Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $139M | $158M | $147M | $148M | $147M | $169M | $219M | $204M | $240M | $282M |
| Revenue growth | — | 14.1% | -7.3% | 0.7% | -0.0% | 14.5% | 30.0% | -7.2% | 18.0% | 17.3% |
| Gross profit | $26.6M | $32.2M | $25.3M | $23.4M | $24.0M | $24.2M | $35.6M | $52.1M | $68.9M | $80.4M |
| Gross margin | 19.2% | 20.3% | 17.3% | 15.9% | 16.3% | 14.3% | 16.2% | 25.5% | 28.6% | 28.5% |
| Operating income | $6.54M | $9.92M | $2.11M | -$2.35M | -$1.32M | -$2.61M | $5.36M | $18.3M | $17.8M | $16.7M |
| Operating margin | 4.7% | 6.3% | 1.4% | -1.6% | -0.9% | -1.5% | 2.4% | 9.0% | 7.4% | 5.9% |
| Net income | $4.51M | $5.28M | $1.53M | -$4.69M | -$3.67M | -$6.13M | $738K | $18.8M | $11.4M | $9.62M |
| Net margin | 3.3% | 3.3% | 1.0% | -3.2% | -2.5% | -3.6% | 0.3% | 9.2% | 4.7% | 3.4% |
| EPS (diluted) | $1.66 | $1.90 | $0.55 | -$1.70 | -$1.33 | -$2.20 | $0.25 | $6.38 | $3.83 | $3.22 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $11.7M | $3.18M | $2.49M | $4.16M | $912K | -$7.88M | -$3.79M | $19.6M | $14.8M | $18.6M |
| Capital expenditures | $2.61M | $3.40M | $4.21M | $2.46M | $2.40M | $1.91M | $4.15M | $4.37M | $2.17M | $3.94M |
| Free cash flow | $9.05M | -$212K | -$1.72M | $1.70M | -$1.49M | -$9.79M | -$7.94M | $15.2M | $12.6M | $14.7M |
| Share buybacks | — | — | — | — | — | — | $0.00 | $2.00M | $1.60M | $0.00 |
| Dividends paid | $1.57M | $1.79M | $2.03M | $1.04M | $0.00 | — | — | — | — | — |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $12.5M | $9.72M | $10.6M | $4.37M | $5.21M | $4.43M | $8.08M | $23.3M | $14.9M | $9.95M |
| Total assets | $80.9M | $85.1M | $87.2M | $83.9M | $89.4M | $119M | $119M | $135M | $195M | $178M |
| Total liabilities | $37.7M | $36.9M | $39.5M | $45.2M | $47.9M | $82.6M | $80.4M | $78.6M | $128M | $101M |
| Long-term debt | $2.43M | $1.26M | $97.0K | $0.00 | — | $0.00 | — | — | $34.7M | $15.1M |
| Shareholders' equity | $43.5M | $47.7M | $47.1M | $38.4M | $41.2M | $35.7M | $37.4M | $54.8M | $64.5M | $74.7M |
| Retained earnings | $39.8M | $43.8M | $43.6M | $37.8M | $34.1M | $28.0M | $28.8M | $47.5M | $58.9M | $68.5M |
| Shares (wtd avg diluted) | 2.73M | 2.78M | 2.79M | 2.75M | 2.76M | 2.79M | 2.90M | 2.94M | 2.98M | 2.98M |
Every figure is extracted from KEWAUNEE SCIENTIFIC CORP /DE/’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.